氨磺必利与利培酮治疗首发精神分裂症疗效与安全性对比分析.docVIP

氨磺必利与利培酮治疗首发精神分裂症疗效与安全性对比分析 　　DOI：10.16662/j.cnki.1674-0742.2017.23.138 　　[摘要] 目的 研究氨磺必利与利培酮治疗首发精神分裂症患者的临床效果安全性。方法 方便选取该院2015年8月―2016年12月期间所收治的64例首发精神分裂症患者进行研究，对患者进行随机分组，研究组和对照组，每组32例，对照组应用利培酮治疗，研究组应用氨磺必利治疗，对比分析两组患者的治疗总有效率与不良反应发生情况（TESS评分），观察两组患者的阴性与阳性综合征量表评分与CDSS评分。结果 研究组治疗总有效率为84.38%，对照组治疗总有效率为81.25%，两组差异无统计学意义（P0.05）。治疗后研究组患者PANSS阴性减分（8.24±5.15）分、CDSS评分（6.41±1.52）分与对照组[（5.62±4.13）分、（5.23±2.40）分]比?^差异有统计学意义，且研究组患者的不良反应发生率（25.00%）显著低于对照组（53.13%），两组差异有统计学意义（P0.05）。结论 在首发精神分裂症患者应用氨磺必利治疗的效果与利培酮相比，差异无统计学意义，但是若患者的临床症状属阴性症状，那么可以应用氨磺必利进行治疗，效果更为明显，且不良反应少，具有较高的安全性，值得推广应用。 　　[关键词] 氨磺必利；利培酮；首发精神分裂症；安全性 　　[中图分类号] R749 [文献标识码] A [文章编号] 1674-0742（2017）08（b）-0138-03 　　Comparative Analysis of the Efficacy and Safety of Amisulpride and Risperidone in the Treatment of First-episode Schizophrenia 　　WANG Yan-hong 　　Department of Psychiatry， Heze No.3 People’s Hospital， Heze， Shandong Province， 274000 China 　　[Abstracts] Objective Objective This paper tries to study the clinical efficacy of amisulpride and risperidone in the treatment of first-episode schizophrenic patients. Methods 64 cases treated in this hospital during August 2015 to December 2016 were conveniently selected and randomly divided into the study group and the control group， with 32 cases in each group， the control group was treated with risperidone treatment， the study group was treated with amisulpride， the total effective rate of treatment and adverse reactions （TESS score） of the two groups were observed， and the negative and positive syndrome scale and CDSS score were observed. Results The total effective rate was 84.38% in the study group， the total effective rate in the control group was 81.25%， there was no significant difference between the two groups（P0.05）； PANSS negative score of the study group after treatment was （8.24±5.15）points， CDSS subtraction was （6.41±1.52）points and that of the control group was（5.62±4.13）points， （5.23±2.40）points， the difference was significantly different， and the incid